On November 3, 2022 Grid Therapeutics, LLC, a clinical-stage biopharmaceutical company developing human-derived antibodies derived from single B cells of cancer patients, reported a poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 37th Annual Meeting (SITC 2022), to be held in Boston, Massachusetts and virtually on November 8-12, 2022 (Press release, Grid Therapeutics, NOV 3, 2022, View Source [SID1234623026]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Title: Interim Results from a Phase IB, First-in-Human Study of a Novel Complement Factor H Inhibitor (GT103) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC)

Abstract Number: 699

Presenter: Dr. Jeffrey Clarke, M.D., Duke Cancer Center Thoracic Clinic, Durham, NC.

Date: Thursday, November 10, 2022, Poster Hall (Hall C) 9 a.m.– 9 p.m. EST

All posters will be available to conference attendees as virtual e-posters during SITC (Free SITC Whitepaper) 2022. The posters will also be available on November 10, 2022, in the News section of the Company’s website at www.gridtherapeutics.com, under Publications and Presentations.

About the Study

The Phase 1 open-label, dose-escalation clinical trial of GT103 is designed to assess the safety and tolerability of GT103 as a single agent. The study enrolled subjects with refractory NSCLC. Key objectives in the study include determining the recommended Phase 2 dose, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity. Please refer to www.clinialtrials.gov for additional clinical trial details.

About SITC (Free SITC Whitepaper)

Established in 1984, the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC (Free SITC Whitepaper) is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC (Free SITC Whitepaper) aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC (Free SITC Whitepaper) at sitcancer.org

On November 3, 2022 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) reported that it will host a conference call at 8:00 a.m. ET Thursday, November 10, 2022 to report financial results for the quarter ended September 30, 2022 and discuss recent corporate highlights (Press release, Aldeyra Therapeutics, NOV 3, 2022, View Source [SID1234623025]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 048610. A live audio webcast of the conference call also will be accessible from the "Investors & Media" section of Aldeyra’s website at View Source

After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.

On November 3, 2022 ATCC, the world’s premier biological materials management and standards organization, reported a new line of products, CAR-T Target luciferase reporter cell lines, that will support immuno-oncology (IO) discovery and development of novel immunotherapies (Press release, American Type Culture Collection (ATCC), NOV 3, 2022, View Source [SID1234623024]). These models have a high endogenous expression of relevant chimeric antigen receptor (CAR)-T target antigens such as HER2, CD19, and CD20. These new IO tools are comprised of both hematological cancer and solid tumor cell lines that express a luciferase reporter.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At ATCC, our mission is to offer the scientific community credible biological products that support incredible achievements in basic science, drug discovery, translational medicine and public health," said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC. "We believe that these innovative CAR-T target cell lines will help mitigate some of the formidable roadblocks that IO researchers encounter in their fight against cancer."

These new IO tools alleviate many of the challenges in evaluating the ex vivo biofunction of CAR-T cells. Coming from highly authenticated and characterized human ATCC cell lines eliminates questions of cell provenance, as well as potential donor-to-donor and cross-species issues. In addition, these lines stably express a sensitive, robust, and easy-to-use reporter system and have been shown in a recent study to display dose-dependent targeting.

"As IO is one of the fastest growing sectors in cancer research and therapeutics, ATCC continues to prioritize the development of solutions to support the global effort in advancing this field," said Fang Tian, Ph.D., Director of Biological Content.

ATCC supports cancer research and drug discovery with thousands of human and animal cancer cell lines for a better understanding of tumor biology, cancer genomics, tumor biomarkers, and advancing novel therapeutics. In addition to providing the most commonly used historical tumor cell lines, ATCC develops genetically engineered cell lines, tumor organoids, reporter cell lines, and drug-resistant cell lines for the global scientific community.

ATCC will be showcasing its immuno-oncology research tools at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2022 Annual Meeting in Boston, Massachusetts, November 8 through November 12, 2022. At booth 313, they will present the poster, "Luciferase reporter cancer cell lines facilitate CAR-T development."

On November 3, 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, reported that members of its executive team will participate in the following upcoming investor conferences (Press release, Aura Biosciences, NOV 3, 2022, View Source [SID1234623023]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel 2022 Healthcare Conference at the Lotte New York Palace on Wednesday, November 16, 2022.
Presentation at 10:55 a.m. ET.
5th Annual 2022 Evercore ISI HealthCONx on Tuesday, November 29, 2022.
Fireside chat at 8:25 a.m. ET.
A live webcast of the Stifel presentation and Evercore ISI fireside chat will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company’s website at View Source, where a replay of the webcasts will be archived for 90 days following the presentation date.

On November 3, 2022 Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, reported that Chief Executive Officer, Brian Lestini, M.D., Ph.D., will present at the 2022 Jefferies London Healthcare Conference on Thursday, November 17, 2022 at 2:40 PM GMT (Press release, Pyramid Biosciences, NOV 3, 2022, View Source [SID1234623022]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible on Pyramid’s website at Jefferies audiocast link or by visiting: View Source A replay of the call will be archived for 90 days after the call.

For more information on the conference or to schedule a one-on-one meeting with the Pyramid Biosciences management, please contact your Jefferies representative.